FoundationOne CDx
Commercial- Indications
- Solid tumors
Company intelligence / Profile preview
Foundation Medicine’s CGP tests are validated and widely used to inform clinical decision-making in oncology. They provide actionable insights for targeted therapies and immunotherapies by identifying clinically relevant genomic alterations. The company collaborates with biopharma partners to accelerate new therapy development but does not itself develop therapeutics. Clinical results focus on the utility of their diagnostics rather than direct patient outcomes.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Foundation Medicine.